Full Press Release Details
Records New Responder with Remarkable Improvement of "Eye-Bulging" Metastatic Tumor
| After only 3 cycles, patient experienced a remarkable improvement of eye-bulging "proptosis" caused by orbital metastatic breast cancer tumor behind the eye. | |
| Significant ocular pain reduction recorded. | |
| Heavily treated patient had 7 prior failed regimens . | |
| The patient continues to receive treatment. |
PA and VANCOUVER, British Columbia, November 30, 2023- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell"
or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is
thrilled to announce a new remarkable responder in our Phase 2 study of the Bria-IMT combination regimen. BriaCell's clinical
team reported a patient with extensive metastatic breast cancer who had failed all available therapies. The patient had cancer behind
the eye, causing proptosis (eye-bulging) and significant pain that were both resolved with BriaCell's treatment.
survival updates and clinical data sets on the entire Phase 2 study cohort will be presented at the San Antonio Breast Cancer Symposium
on December 6th and 7th, 2023.
like this are not often seen in heavily pretreated patients and are especially rare in metastatic disease to the eye," stated Carmen
Calfa, M.D., Clinical Research Lead for the breast site disease group at the University of Miami Miller School of Medicine, Co-Director
of the Cancer Survivorship Program at Sylvester Comprehensive Cancer Center, and Principal Clinical Investigator of the Phase 2 Bria-IMT
study. "We were excited to offer her the latest treatments and thrilled to share in her success and joy."
noted responder, a post-menopausal metastatic breast cancer patient (the "Remarkable Responder"), experienced a remarkable
improvement of proptosis caused by breast cancer tumors behind the eye, resulting in significant pain reduction in the ocular region.
Her disease is characterized as positive for hormone receptor and 3+ for HER2. The woman had extensive metastatic disease (i.e. breast
cancer tumors that have migrated to other areas of the body) including the bones of the spine, pelvis, sternum, the skull, and face,
which included proptosis of the right eye from which the patient was clinically blind in that eye.
patient was heavily pre-treated (7 prior regimens) highlighting the remarkable nature of her response on BriaCell's treatment despite
her very advanced cancer stage. Her last disease progression was recorded in August 2023. The patient started on BriaCell's Bria-IMT
combination therapy on October 4, 2023 and has received only 3 cycles of therapy. The Bria-IMT combination regimen has been well
tolerated and the patient remains on treatment.
had previously reported a similar case of a remarkable response with 100% resolution of an eye-bulging orbital tumor (release here).
This particular patient had received (and failed) 12 regimens with 16 agents (incl. 13 chemotherapies) prior to BriaCell's treatment,
again adding to the remarkable nature of her response.
are reporting remarkable clinical responses in patients who were previously thought untreatable, suggesting effectiveness in difficult-to-reach
tumors such as those in the bones and the brain," said Dr. William V. Williams,
BriaCell's President and CEO. "We hypothesize that our Bria-IMT regimen may cross the blood brain barrier to treat these difficult-to-reach areas, such as the brain,
which continues to increase our excitement for our novel cancer immunotherapy. We have seen several patients with central nervous system
metastases respond to our therapy and are looking forward to further investigating this unique observation in our pivotal Phase 3 study
of Bria-IMT combination therapy in advanced metastatic breast cancer."
BriaCell Therapeutics Corp.
is a clinical-stage biotechnology company that develops
novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will," "would," or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements, including those about: the presentation of additional survival updates and
clinical data sets on the entire Phase 2 study cohort at the San Antonio Breast Cancer Symposium on December 6th and 7th, 2023; whether
the remarkable responder patient will remain on the treatment; the potential effectiveness of BriaCell's treatment, including for
difficult-to-reach tumors such as those in the bones and the brain; and whether the Bria-IMT regimen may cross the blood brain
barrier to treat these difficult-to-reach areas, such as the brain; and are subject to inherent uncertainties, risks, and assumptions
that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not
prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties"
in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's
most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian
securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's
profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this
announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required
under applicable law.
the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange)
accepts responsibility for the adequacy or accuracy of this release.
William V. Williams, MD
Director of Public Relations